1Corzo JE,Gomez-Mateos J,Rueda A.Relationship between low bone mineral density and highly active antiretroviral therapy including protease inhibitors in HIV-infected patients[J].HIV Clin Trials,2003,4(5):337-346.
2Shah SS,Rodriguez T,McGowan JP.Miller Fisher variant of Guillain-Barre syndrome associated with lactic acidosis and stavudine therapy.Clin Infect Dis[J].2003,36(10):131-133.
3Montaner IS,Cote HC,Harris M.Mitochnodrial toxicity in the era of HA ART:evaluating venous lactate and peripheral blood mitochnodrial DNA in HIV-infected patients taking antiretr oviral therapy[J].J Acquir Immune Defic Syndr,2003,34 Suppl(1):S85-90.
4Gerard Y,Viget N,Yazdanpanah Y.Hyperlactataemia during antiretrovir al therapy:incidences,clinical data and treatment[J].Therapie,2003,58(2):153-158.
5Kontorinis N,Dieterich DT.Toxicity of non-nucleoside analogue reve rse transcriptase inhibitors[J].Semin Li ver Dis,2003,23(2):173-182.
6Rhew DC,Bernal M,Aguilar D,et al.Association between protease in hibitor use and increased cardiovascular risk in patients infected with human immunodeficiency virus:a system atic review[J].Clin Infect Dis,2003,37(7):959-972.
9McComsey G,Maa JF.Host factors maybe more important than choice of antiretrovirals in the development of lipoatrophy[J].AIDS Read,2003,13(11):539-542,559.
10Chow DC,Souza SA,Chen R.Elevated blood pressure in HIV-infected individuals receiving highly active antir etroviral therapy[J].HIV Clin Trials,2003,4(6):411-416.
3Jones SG.Taking HAART: how to support patient s with HIV/ AIDS. Nursing,2001,31(12) :36 42.
4Coetzee D, Hildebrand K,Boulle A,et al. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS,2004,18(6) :887-895.
5Egger M,May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antlretrovlral therapy:a collaborative analysis of prospective studies. Lancet, 2002, 360 (9327) : 119- 129.
